Kailera Therapeutics
KLRA
11.02
-0.56
-4.84%
Kailera Therapeutics
US · KLRA
#3073 by market cap
Listed 2026
11.02
-0.56
-4.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy RatingMarket Newswire · 2026/5/27
-
Rating change
A Quick Look at Today's Ratings for Kailera Therapeutics(KLRA.US), With a Forecast Between $30 to $48Market Newswire · 2026/5/12
-
Rating change
Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/7/8
-
Rating change
Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/5/18
-
Rating change
Kailera Therapeutics, Inc. (KLRA) Receives a Buy From TD CowenTipRanks · 2026/5/22
-
Rating change
Analysts Offer Insights on NA Companies: Douglas AG (OtherDOUDF) and Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/5/12
-
Rating change
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57Market Newswire · 2026/7/8
-
Rating change
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/7/8
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/8/13
-
Rating change
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy RatingMarket Newswire · 2026/5/13
-
Rating change
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57Market Newswire · 2026/5/13
-
TD Cowen Sticks to Its Buy Rating for Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/9/30
-
Rating change
Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Kailera Therapeutics, Inc. (KLRA)TipRanks · 2026/8/14
-
Rating change
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/8/13
-
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57Market Newswire · 2026/9/30
-
Rating change
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA), Warby Parker (WRBY) and Aprea Therapeutics (APRE)TipRanks · 2026/8/13
-
CCORF Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $44Market Newswire · 2026/11/9
-
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy RatingMarket Newswire · 2026/9/30
-
Rating change
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/8/14
-
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)TipRanks · 2026/9/30
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Kailera Therapeutics discussion 0 comments